Format

Send to

Choose Destination
J Pharm Biomed Anal. 2019 Jan 5;162:82-90. doi: 10.1016/j.jpba.2018.09.021. Epub 2018 Sep 11.

Urinary and plasma metabolite differences detected by HPLC-ESI-QTOF-MS in systemic sclerosis patients.

Author information

1
Research and Development of Functional Food Centre (CIDAF), Health Science Technological Park, Granada, Spain; Department of Analytical Chemistry, Faculty of Sciences, University of Granada, Granada, Spain.
2
Research and Development of Functional Food Centre (CIDAF), Health Science Technological Park, Granada, Spain.
3
Research and Development of Functional Food Centre (CIDAF), Health Science Technological Park, Granada, Spain. Electronic address: iborras@cidaf.es.
4
Eli Lilly and Company, Indianapolis, United States.
5
Centre for Genomics and Oncological Research (GENYO) Pfizer, University of Granada, Andalusian Government, Health Science Technological Park, Granada, Spain.
6
Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy.

Abstract

Systemic Sclerosis (SSc) is a chronic autoimmune disease whose origin and pathogenesis are not yet well known. Recent studies are allowing a better definition of the disease. However, few studies have been performed based on metabolomics. In this way, this study aims to find altered metabolites in SSc patients in order to improve their diagnosis, prognosis and treatment. For that, 59 SSc patients and 28 healthy volunteers participated in this study. Urine and plasma samples were analysed by a fingerprinting metabolomic approach based on HPLC-ESI-QTOF-MS. We observed larger differences in urine than plasma metabolites. The main deregulated metabolic families in urine were acylcarnitines, acylglycines and metabolites derived from amino acids, specifically from proline, histidine and glutamine. These results indicate perturbations in fatty acid beta oxidation and amino acid pathways in scleroderma patients. On the other hand, the main plasma biomarker candidate was 2-arachidonoylglycerol, which is involved in the endocannabinoid system with potential implications in the induction and propagation of systemic sclerosis and autoimmunity.

KEYWORDS:

2-arachidonoylglycerol; Acylcarnitines; Biomarker; HPLC-ESI-QTOF-MS; Metabolomics; Systemic sclerosis

PMID:
30227356
DOI:
10.1016/j.jpba.2018.09.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center